Respiratory Syncytial Virus (Treatment)

Inhalation Technology Used To Treat Respiratory Syncytial Virus

Published in TB and Outbreaks Week, January 11th, 2000

ViroPharma Incorporated and Battelle Pulmonary Therapeutics, a division of Battelle Memorial Institute, announced that they have entered into a license agreement using Battelle's inhalation drug delivery device technology.

ViroPharma will use Battelle's inhalation technology in combination with ViroPharma's small molecule antiviral drug candidates for the treatment of respiratory syncytial virus (RSV) disease. ViroPharma is responsible for the development, manufacturing, and commercialization of all RSV products.

"RSV disease represents a serious health threat to individuals of all ages," said Claude H. Nash, ViroPharma. "There is an urgent need...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2000-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry